Markus Schulze

Markus Schulze

Auto-generated profile, based on publicly available information

Markus Schulze

Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Journal of Biotechnology
Verified
Journal Article
Open access
MSMarkus Schulze
Markus Schulze
JLJohannes Lemke
Johannes Lemke
DPDavid Pollard
David Pollard
RWRene H. Wijffels
Rene H. Wijffels
JMJens Matuszczyk
Jens Matuszczyk
DMDirk E. Martens
Dirk E. Martens
Current CHO cell production processes require an optimized space-time-yield. Process intensification can support achieving this by enhancing the productivity and improving facility utilization. The use of perfusion at the last stage of the seed train (N-1) for high cell density inoculation of the fed-batch N-stage production culture is a relatively new approach with few industry applicable examples. Within this work, the impact of the cell-specific perfusion rate (CSPR) of the N-1 perfusion and the relevance of its control for the quality of generated inoculation cells was evaluated using an automated perfusion rate (PR) control based on online biomass measurements. Precise correlations (R² = 0.99) between permittivity and viable cell counts were found up to the high densities of 100⋅106 c·mL−1. Cells from N-1 perfusion were cultivated at a high and low CSPR with 50 and 20 pL·(c·d)−1, respectively. Lowered cell growth and an increased apoptotic reaction was found as a consequence of the latter due to nutrient limitations and reduced uptake rates. Subsequently, batch cultivations (N-stage) from the different N-1 sources were inoculated to evaluate the physiological state of the inoculum. Successive responses resulting from the respective N-1 condition were uncovered. While cell growth and productivity of approaches inoculated from high CSPR and a conventional seed were comparable, low CSPR inoculation suffered significantly in terms of reduced initial cell growth and impaired viability. This study underlines the importance to determine the CSPR for the design and implementation of an N-1 perfusion process in order to achieve the desired performance at the crucial production stage.

20 September 2021 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
MSMarkus Schulze
Markus Schulze
JNJulia Niemann
Julia Niemann
RWRene H. Wijffels
Rene H. Wijffels
JMJens Matuszczyk
Jens Matuszczyk
Dirk MartensDirk Martens
Dirk Martens
Currently, the mammalian biomanufacturing industry explores process intensification (PI) to meet upcoming demands of biotherapeutics while keeping production flexible but, more importantly, as economic as possible. However, intensified processes often require more development time compared with conventional fed-batches (FBs) preventing their implementation. Hence, rapid and efficient, yet straightforward strategies for PI are needed. In this study we demonstrate such a strategy for the intensification of an N-stage FB by implementing N-1 perfusion cell culture and high inoculum cell densities resulting in a robust intensified FB (iFB). Furthermore, we show successful combination of such an iFB with the addition of productivity enhancers, which has not been reported so far. The conventional CHO cell FB process was step-wise improved and intensified rapidly in multi-parallel small-scale bioreactors using N-1 perfusion. The iFBs were performed in 15 and 250 mL bioreactors and allowed to evaluate the impact on key process indicators (KPI): the space-time yield (STY) was successfully doubled from 0.28 to 0.55 g∙(L∙d)-1, while product quality was maintained. This gain was generated by initially increasing the inoculation density, thus shrinking process time, and secondly supplementation with butyric acid (BA), which reduced cell growth and enhanced cell-specific productivity from ~25 to 37 pg∙(cell∙d)-1. Potential impacts of PI on cell metabolism were evaluated using flux balance analysis. Initial metabolic differences between the standard and intensified process were observed but disappeared quickly. This shows that PI can be achieved rapidly for new as well as existing processes without introducing sustained changes in cellular and metabolic behavior.

24 June 2022 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
MSMarkus Schulze
Markus Schulze
YKYadhu Kumar
Yadhu Kumar
MRMerle Rattay
Merle Rattay
JNJulia Niemann
Julia Niemann
RWRene H. Wijffels
Rene H. Wijffels
DMDirk E. Martens
Dirk E. Martens
Process intensification is increasingly used in the mammalian biomanufacturing industry. The key driver of this trend is the need for more efficient and flexible production strategies to cope with the increased demand for biotherapeutics predicted in the next years. Therefore, such intensified production strategies should be designed, established, and characterized. We established a CHO cell process consisting of an intensified fed‐batch (iFB), which is inoculated by an N‐1 perfusion process that reaches high cell concentrations (100 × 106 c ml−1). We investigated the impact of butyric acid (BA) supplementation in this iFB process. Most prominently, higher cellular productivities of more than 33% were achieved, thus 3.5 g L−1 of immunoglobulin G (IgG) was produced in 6.5 days. Impacts on critical product quality attributes were small. To understand the biological mechanisms of BA in the iFB process, we performed a detailed transcriptomic analysis. Affected gene sets reflected concurrent inhibition of cell proliferation and impact on histone modification. These translate into subsequently enhanced mechanisms of protein biosynthesis: enriched regulation of transcription, messenger RNA processing and transport, ribosomal translation, and cellular trafficking of IgG intermediates. Furthermore, we identified mutual tackling points for optimization by gene engineering. The presented strategy can contribute to meet future requirements in the continuously demanding field of biotherapeutics production.

1 January 1990 in Physica Scripta
Verified
Journal Article
Closed access
PDF file
MMMichael Meyer
Michael Meyer
MPM Pahler
M Pahler
TPTh Prescher
Th Prescher
ERE V Raven
E V Raven
MRM Richter
M Richter
PZP Zimmermann
P Zimmermann
The combined use of synchrotron and laser radiation for photoelectron spectroscopy of free atoms is described with special emphasis on the polarization of both radiation sources. By the absorption of the polarized laser radiation an atomic alignment or orientation is produced which has a strong influence on the subsequent absorption of the polarized synchrotron radiation and on the angular distribution of the photoelectrons.

9 November 1995 in Electronics Letters
Verified
Journal Article
Closed access
JYJ. Yu
J. Yu
DHD. Huhse
D. Huhse
MSM. Schell
M. Schell
MSM. Schulze
M. Schulze
Dieter BimbergDieter Bimberg
Dieter Bimberg
IBI. Bennion
I. Bennion
A chirped Bragg grating fibre external cavity semiconductor laser is hybridly modelocked to generate light pulses with perfectly linear wavelength chirp, resulting in Fourier-transform-limited 2.5 ps pulses incorporated with subsequent chirp compensation. The setup facilitates wavelength tunability across the whole grating bandwidth (15 nm) by changing the modulation frequency.

28 October 2022 in Chemie Ingenieur Technik
Verified
Journal Article
Open access
MSMarkus Schulze
Markus Schulze
DKDominic Kues
Dominic Kues
WGWei Gao
Wei Gao
MHMatthew Houser
Matthew Houser
KSKarl‐Heinz Scheibenbogen
Karl‐Heinz Scheibenbogen
GGGerhard Greller
Gerhard Greller
Production of biopharmaceuticals needs to become faster, more flexible, and efficient. Perfusion processes allow to operate cell cultivations at higher cell concentrations, shorten their process time and increase their productivity. Still, either customized software solutions or third‐party stand‐alone control devices are often used for perfusion control. Its integration into a bioreactor automation platform will simplify the implementation and application of perfusion processes in the future. In this study, the automation of an integrated perfusion control strategy for a scalable single‐use bioreactor family is demonstrated. The control strategy is illustrated by means of a CHO cell N–1 perfusion process in a 50‐L bioreactor. Accurate control allowed to achieve 80 · 106 c mL−1 within five days. Furthermore, also DO and pH setpoints were precisely controlled throughout the N–1 perfusion process. Finally, the advantage of this process strategy is exemplified by comparing fed‐batch processes inoculated from N–1 perfusion vs. N–1 batch processes.